Weekly Paclitaxel Plus Bevacizumab versus Docetaxel As Second- or Third-Line Treatment in Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC): Results of the IFCT-1103 ULTIMATE Study
Keyword(s):
Keyword(s):
2009 ◽
Vol 71
(2)
◽
pp. 117-126
◽
Keyword(s):
2016 ◽
Vol 34
(15_suppl)
◽
pp. 9005-9005
◽
Keyword(s):
Keyword(s):
Keyword(s):
2013 ◽
Vol 15
(5)
◽
pp. 343-357
◽
Keyword(s):
Keyword(s):
Keyword(s):